Heron Therapeutics (HRTX) PT Raised to $46 at Leerink Partners; 'Focus Moving to HTX-011's Commercialization'
Tweet
Share
E-mailGet Alerts HRTX Hot Sheet
Price: $0.42 +7.69%
Rating Summary:
18 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 1 | Down: 0 | New: 0
Rating Summary:
18 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 1 | Down: 0 | New: 0
Join SI Premium – FREE
Leerink Partners raised its price target on Heron Therapeutics (NASDAQ: HRTX) to $46.00 (from $36.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Upgrades YDUQS Participacoes SA (YDUQ3:BZ) to Overweight
- Grupo Bimbo SAB de CV (BIMBOA:MM) (GRBMF) PT Raised to Peso57 at JPMorgan
- Samsung Electronics Co (005935:KS) PT Raised to KRW374,000 at Bernstein SocGen Group
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
